Qure N.V. recently announced positive topline results from its pivotal Phase I/II trial of AMT-130, demonstrating statistically significant slowing of Huntington's disease progression, and entered ...

Tylah Tully speaks with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn about the company’s latest funding success, regulatory milestones, and clinical development strategy.

Juventus will reveal their balance sheets for the 2024/2025 season during a meeting of the board later this week. It could ...

Immutep ( ($IMMP) ) just unveiled an announcement. On September 22, 2025, Immutep announced a research collaboration with the George Washington ...

Lumen Technologies has seen a slight uptick in its consensus analyst price target, increasing from $5.06 to $5.20. This ...

AMD faces rising inventory levels, softening demand signals, and insider selling, with valuation still elevated amid GPU ...

PayPal Holdings, Inc. (NASDAQ:PYPL) and alternative asset manager Blue Owl Capital Inc. (NYSE:OWL) announced a two-year ...

Co-development agreement with US insulin pump device company for AT278 and sale of royalty and technology access fees for up ...

EMVision just raised fresh cash to push its portable stroke scanners through pivotal trials and FDA clearance.

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ('UK MAR').

Sempra (NYSE:SRE) announced a $10 billion deal to sell a 45% stake in Sempra Infrastructure Partners to affiliates of KKR & Co (NYSE:KKR) and Canada Pension Plan Investment Board. The transaction is ...

(NASDAQ: MDCX) is a clinical-stage biotech company working on disruptive approaches to cancer and urologic disease. The ...